Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Current Controversies in Chronic Obstructive Pulmonary Disease: A Report from the GOLD Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2018 Nov 14. doi: 10.1513/AnnalsATS.201808-557PS. [Epub ahead of print] No abstract available.

PMID:
30427736
2.

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort.

Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.

3.

Medical Treatment of COPD.

Graf J, Jörres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH.

Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605. doi: 10.3238/arztebl.2018.0599.

4.

Pro-viral miRNAs detected in BALF extracellular vesicles of patients with influenza virus-induced ARDS.

Scheller N, Herold S, Kellner R, Bertrams W, Jung AL, Janga H, Greulich T, Schulte LN, Vogelmeier CF, Lohmeyer J, Schmeck B.

J Infect Dis. 2018 Sep 15. doi: 10.1093/infdis/jiy554. [Epub ahead of print]

PMID:
30239899
5.

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.

Buhl R, Criée CP, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 24;13:2557-2568. doi: 10.2147/COPD.S169958. eCollection 2018.

6.

Influence of body mass on predicted values of static hyperinflation in COPD.

Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.

7.

COPD as a risk factor of the complications in lower limb arthroplasty: a patient-matched study.

Klasan A, Dworschak P, Heyse TJ, Ruchholtz S, Alter P, Vogelmeier CF, Schwarz P.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 21;13:2495-2499. doi: 10.2147/COPD.S161577. eCollection 2018.

8.

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency.

Greulich T, Rodríguez-Frias F, Belmonte I, Klemmer A, Vogelmeier CF, Miravitlles M.

Respir Res. 2018 Aug 13;19(1):151. doi: 10.1186/s12931-018-0826-8.

9.

[Antibiotics: The Most Important Discovery in Medicine of the 20th Century].

Vogelmeier CF.

Dtsch Med Wochenschr. 2018 Aug;143(15):1057. doi: 10.1055/a-0606-1729. Epub 2018 Jul 30. German. No abstract available.

PMID:
30060272
10.

Design and application of an MR reference phantom for multicentre lung imaging trials.

Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jörres RA, Kauczor HU, Heußel CP, Wielpütz MO, Jobst BJ.

PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.

11.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

12.

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.

Kardos P, Mokros I, Sauer R, Vogelmeier CF.

Int J Chron Obstruct Pulmon Dis. 2018 May 3;13:1455-1468. doi: 10.2147/COPD.S159827. eCollection 2018.

13.

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.

PMID:
29742906
14.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

15.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

16.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
17.

Blood eosinophils as a marker of eosinophilic exacerbations in COPD.

Greulich T, Vogelmeier CF.

Lancet Respir Med. 2018 May;6(5):e17. doi: 10.1016/S2213-2600(18)30095-X. Epub 2018 Apr 5. No abstract available.

PMID:
29627195
18.

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.

Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.

19.

Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling.

Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.

PMID:
29605197
20.

Exacerbations of COPD.

Viniol C, Vogelmeier CF.

Eur Respir Rev. 2018 Mar 14;27(147). pii: 170103. doi: 10.1183/16000617.0103-2017. Print 2018 Mar 31. Review.

21.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

22.

Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, Blasi F, Vogelmeier CF.

Respir Res. 2018 Jan 18;19(1):11. doi: 10.1186/s12931-018-0715-1. Review.

23.

The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.

Wacker ME, Kitzing K, Jörres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017.

24.

Prevalence of comorbidities in COPD patients by disease severity in a German population.

Greulich T, Weist BJD, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, Alter P, Vogelmeier CF.

Respir Med. 2017 Nov;132:132-138. doi: 10.1016/j.rmed.2017.10.007. Epub 2017 Oct 12.

PMID:
29229085
25.

Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):968-969. doi: 10.1164/rccm.201710-2027LE. No abstract available.

PMID:
29140725
26.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
27.

GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.

Worth H, Buhl R, Criée CP, Kardos P, Lossi NS, Vogelmeier CF.

Respir Med. 2017 Oct;131:77-84. doi: 10.1016/j.rmed.2017.08.008. Epub 2017 Aug 9.

28.

Cardiovascular risk in patients with alpha-1-antitrypsin deficiency.

Fähndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jörres RA, Greulich T, Vogelmeier CF, Bals R; COSYCONET investigators.

Respir Res. 2017 Sep 15;18(1):171. doi: 10.1186/s12931-017-0655-1.

29.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.

30.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

31.

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1230-1231. doi: 10.1164/rccm.201706-1105LE. No abstract available.

PMID:
28650724
32.

[Orphan diseases - on the way to better patient care].

Vogelmeier CF.

Dtsch Med Wochenschr. 2017 Jun;142(11):777-778. doi: 10.1055/s-0043-100842. Epub 2017 May 31. German. No abstract available.

PMID:
28564726
33.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.

34.

Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study.

Boeselt T, Nell C, Lütteken L, Kehr K, Koepke J, Apelt S, Veith M, Beutel B, Spielmanns M, Greulich T, Vogelmeier CF, Kenn K, Janciauskiene S, Alter P, Koczulla AR.

Respiration. 2017;93(5):301-310. doi: 10.1159/000464139. Epub 2017 Mar 23.

35.

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197. doi: 10.1164/rccm.201701-0193OC.

36.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Jul;53(7):411-412.

37.

Myocardial homing of mesenchymal stem cells following intrapericardial application and amplification by inflammation - an experimental pilot study.

Jung N, Rupp H, Koczulla AR, Vogelmeier CF, Alter P.

Can J Physiol Pharmacol. 2017 Sep;95(9):1064-1066. doi: 10.1139/cjpp-2016-0373. Epub 2017 Feb 23.

38.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Eur Respir J. 2017 Mar 6;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar. Erratum in: Eur Respir J. 2017 Jun 22;49(6):.

39.

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Respirology. 2017 Apr;22(3):575-601. doi: 10.1111/resp.13012. Epub 2017 Mar 7.

40.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.

41.

Altered blood levels of vitamin D, cathelicidin and parathyroid hormone in patients with sepsis-a pilot study.

Greulich T, Regner W, Branscheidt M, Herr C, Koczulla AR, Vogelmeier CF, Bals R.

Anaesth Intensive Care. 2017 Jan;45(1):36-45.

42.

[Chest pain : Possible sign of a life-threatening condition].

Welte T, Vogelmeier CF.

Internist (Berl). 2017 Jan;58(1):1-2. doi: 10.1007/s00108-016-0176-x. German. No abstract available.

PMID:
28058457
43.

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.

Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.

Respir Med. 2017 Jan;122:58-66. doi: 10.1016/j.rmed.2016.11.011. Epub 2016 Nov 14.

44.

[International competitive clinical research].

Vogelmeier CF.

Dtsch Med Wochenschr. 2016 Nov;141(24):1734. Epub 2016 Nov 30. German. No abstract available.

PMID:
27903021
45.

New concepts in asthma: clinical phenotypes and pathophysiological mechanisms.

Koczulla AR, Vogelmeier CF, Garn H, Renz H.

Drug Discov Today. 2017 Feb;22(2):388-396. doi: 10.1016/j.drudis.2016.11.008. Epub 2016 Nov 17. Review.

PMID:
27867084
46.

The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database.

Greulich T, Nell C, Hohmann D, Grebe M, Janciauskiene S, Koczulla AR, Vogelmeier CF.

Eur Respir J. 2017 Jan 4;49(1). pii: 1600154. doi: 10.1183/13993003.00154-2016. Print 2017 Jan.

47.

Indacaterol-Glycopyrronium for COPD.

Wedzicha JA, Banerji D, Vogelmeier CF.

N Engl J Med. 2016 Sep 1;375(9):899-900. doi: 10.1056/NEJMc1609305. No abstract available.

48.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators.

N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.

49.

Wall stress determines systolic and diastolic function--Characteristics of heart failure.

Alter P, Koczulla AR, Nell C, Figiel JH, Vogelmeier CF, Rominger MB.

Int J Cardiol. 2016 Jan 1;202:685-93. doi: 10.1016/j.ijcard.2015.09.032. Epub 2015 Sep 25.

PMID:
26454537
50.

Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis.

Greulich T, Vogelmeier CF.

Ther Adv Respir Dis. 2016 Feb;10(1):72-84. doi: 10.1177/1753465815602162. Epub 2015 Sep 4. Review.

Supplemental Content

Loading ...
Support Center